Interaction Checker

Busulfan interactions

Busulfan (Myleran, Busulfex) has 37 documented interactions across the FDA labels and fact sheets we index: 3 major, 4 moderate, 30 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (3)

  • Bismuth subcitrate, metronidazole, and tetracyclineantibioticMajor

    Do not administer bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride concomitantly with busulfan unless the benefit outweighs the risk. (Bismuth subcitrate, metronidazole, and tetracycline label, Warnings and precautions)

  • CyclophosphamideimmunosuppressantMajor

    Hepatic veno-occlusive disease, which may be life threatening, has been reported in patients receiving busulfan, usually in combination with cyclophosphamide or other chemotherapeutic agents prior to bone marrow transplantation. (Busulfan label, Warnings)

  • MetronidazoleantibioticMajor

    Busulfan : Increased busulfan serum concentrations; avoid concomitant use, monitor for plasma concentrations and adjust the busulfan dose accordingly. (Metronidazole label, Drug interactions)

Moderate interactions (4)

  • Deferasiroxiron supplementModerate

    Deferasirox increases exposure of busulfan. (Deferasirox label, Drug interactions)

  • IfosfamideModerate

    Hemorrhagic cystitis is dose‑dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment. (Ifosfamide label, Warnings and precautions)

  • Itraconazoleazole antifungalModerate

    The concomitant systemic administration of itraconazole to patients receiving high-dose MYLERAN may result in reduced busulfan clearance (see CLINICAL PHARMACOLOGY). (Busulfan label, Drug interactions)

  • ThiotepaModerate

    Hepatic Veno-Occlusive Disease Hepatic veno-occlusive disease may occur in patients who have received high-dose TEPADINA in conjunction with busulfan and cyclophosphamide [ see Adverse Reactions (6.1) ]. (Thiotepa label, Warnings and precautions)

Minor mentions (30)

  • Azelastine and fluticasoneantihistamineMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • BeclomethasonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • BetamethasonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • BudesonidecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • Budesonide and formoterolcorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • CiclesonidecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • ClobetasolcorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • DeflazacortcorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • DesonidecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • DexamethasonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • FludrocortisonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • FlunisolidecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • FluocinonidecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • FluticasonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • Fluticasone and salmeterolcorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • HalobetasolcorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • HydrocortisonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • Levothyroxinethyroid hormoneMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan label, Warnings)

  • Levothyroxine and liothyroninethyroid hormoneMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan label, Warnings)

  • Liothyroninethyroid hormoneMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan label, Warnings)

  • MercaptopurineantimetaboliteMinor

    During the pregnancy that resulted in the malformed infant, the mother received x-ray therapy early in the first trimester, mercaptopurine until the third month, then busulfan until delivery. (Busulfan label, Warnings)

  • Methimazoleantithyroid drugMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan label, Warnings)

  • MethylprednisolonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • MometasonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • Olopatadine and mometasoneantihistamineMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • PrednisolonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • PrednisonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

  • Propylthiouracilantithyroid drugMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan label, Warnings)

  • Teriparatidethyroid hormoneMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Busulfan label, Warnings)

  • TriamcinolonecorticosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan label, Warnings)

Check Busulfan against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.